Abbott Laboratories Acquires Exact Sciences for $21 Billion to Expand Cancer Diagnostics Portfolio
核心洞察
Abbott Laboratories has agreed to acquire cancer diagnostics specialist Exact Sciences (搜索) for $21 billion, offering shareholders $105 per share in cash representing a 22% premium.
The acquisition will accelerate Abbott's expansion into the $60 billion U.S. cancer screening and diagnostics industry, combining Abbott's global reach with Exact Sciences (搜索)' innovative testing portfolio.
Exact Sciences (搜索) brings leading cancer detection technologies including the noninvasive Cologuard (搜索) colorectal cancer screening test and the recently launched Cancerguard (搜索) multi-cancer early detection test.
Abbott Laboratories has agreed to acquire cancer diagnostics specialist Exact Sciences (搜索) for $21 billion in an all-cash transaction that will significantly expand Abbott's presence in the rapidly growing cancer screening and diagnostics market. Under the deal terms, Exact Sciences stockholders will receive $105 per share in cash, representing a nearly 22% premium to the company's Wednesday closing price.
Strategic Expansion into Cancer Diagnostics
The acquisition positions Abbott to accelerate its push into the $60 billion U.S. cancer screening and diagnostics industry. Exact Sciences (搜索) has established itself as a leader in this expanding market through its innovative portfolio of cancer detection technologies, including the noninvasive Cologuard (搜索) colorectal cancer screening test and the recently launched Cancerguard (搜索), which represents the first commercially available multi-cancer early detection test.
"Abbott's culture of innovation and global commercial reach will help accelerate our mission of eradicating cancer and expanding access to our tests worldwide, while delivering immediate and substantial value to our shareholders," said Exact Sciences (搜索) CEO Kevin Conroy in a press release announcing the transaction.
Abbott CEO Robert Ford emphasized the complementary nature of the acquisition, stating, "Exact Sciences (搜索)' innovation, strong brand, and customer-focused execution are unrivaled in the cancer diagnostics space, and its presence and strengths are complementary to our own."
Addressing Growing Cancer Burden
The strategic combination comes as cancer diagnosis rates continue to rise globally. According to the companies, roughly 2 million Americans and 20 million people worldwide are diagnosed with cancer annually, with these numbers projected to increase in the coming years. The merged entity aims to leverage Abbott's global commercial infrastructure alongside Exact Sciences (搜索)' diagnostic innovations to improve early cancer detection and treatment outcomes.
"Together with Abbott, we can reach more patients, advance earlier detection, and deliver answers that change lives," Conroy noted, highlighting the potential for expanded patient access through Abbott's international presence.
Transaction Timeline and Approval Process
The $21 billion acquisition is projected to close in the second quarter of 2026, subject to standard regulatory approvals and Exact Sciences (搜索) shareholder approval. The deal follows speculation that emerged earlier this week when Bloomberg reported that the two healthcare companies were in advanced discussions regarding a potential buyout.
Prior to the official announcement, Exact Sciences (搜索) shares experienced significant volatility, with the stock surging nearly 24% on Wednesday following initial reports of the potential acquisition. The formal announcement on Thursday drove additional gains, with shares climbing more than 17% as investors responded positively to the confirmed transaction terms and strategic rationale.